Impact of Next-Generation Flow (NGF) Minimal Residual Disease (MRD) Monitoring in Multiple Myeloma (MM): Results from the Pethema/GEM2012 Trial

被引：0
作者：
Paiva, Bruno
Puig, Noemi
Cedena, Maria Teresa
Cordon, Lourdes
Vidriales, Maria-Belen
Burgos, Leire
Flores-Montero, Juan
Lopez-Anglada, Lucia
Gutierrez, Norma
Calasanz, Maria Jose
Martin-Ramos, Maria Luisa
Garcia-Sanz, Ramon
Martinez-Lopez, Joaquin
Oriol, Albert
Blanchard, M. Jesus
Rios, Rafael
Martin, Jesus
Martinez, Rafael
Sarra, Josep
Hernandez, Miguel T.
de la Rubia, Javier
Krsnik, Isabel
Moraleda, Jose M.
Palomera, Luis
Bargay, Juan
Orfao, Alberto
Rosinol, Laura
Mateos, Maria-Victoria
Lahuerta, Juan-Jose
Blade, Joan
San Miguel, Jesus F.
机构：
来源：
BLOOD | 2017年 / 130卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
905
引用
收藏
页数：2
相关论文
共 50 条
[31]   Eight-color multiparameter flow cytometry (EuroFlow-NGF) is as sensitive as next-generation sequencing in detecting minimal/measurable residual disease in autografts of patients with multiple myeloma [J].
Urushihara, Ryota ;
Takezako, Naoki ;
Yoroidaka, Takeshi ;
Yamashita, Takeshi ;
Murata, Ryoichi ;
Satou, Kenji ;
Nakao, Shinji ;
Takamatsu, Hiroyuki .
EJHAEM, 2023, 4 (01) :184-191
[32]   MONITORING OF MINIMAL RESIDUAL DISEASE (MRD) IN PATIENTS WITH MULTIPLE MYELOMA (MM) BEFORE AND AFTER AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT) [J].
Galtseva, I. ;
Mendeleeva, L. ;
Pokrovskaya, O. ;
Kastrikina, I. ;
Urnova, E. ;
Kuzmina, L. ;
Parovichnikova, E. ;
Savchenko, V. .
HAEMATOLOGICA, 2014, 99 :647-647
[33]   Minimal Residual Disease (MRD) at 106 Measured By Next Generation Flow (NGF) during Daratumumab Consolidation Therapy: Analysis at 18 Months Follow up of DART4MM Study (Daratumumab Treatment For Multiple Myeloma Eradication) [J].
Gozzetti, Alessandro ;
Raspadori, Donatella ;
Pacelli, Paola ;
Antonioli, Elisabetta ;
Bestoso, Elena ;
Ciofini, Sara ;
Bacchiarri, Francesca ;
Buda, Gabriele ;
Tocci, Dania ;
Cafarelli, Cristiana ;
Liberati, Anna Marina ;
Galieni, Piero ;
Navei, Giulia Lucco ;
Occhini, Ubaldo ;
Sicuranza, Anna ;
Staderini, Michela ;
Crupi, Rosaria ;
Petrini, Mario ;
Bosi, Alberto ;
Bocchia, Monica .
BLOOD, 2020, 136
[34]   Comparison of Minimal Residual Disease Detection between the Manual and Automated Gating Strategies of Euroflow Next-Generation Flow in Patients with Multiple Myeloma [J].
Takamatsu, Hiroyuki ;
Yoroidaka, Takeshi ;
Yamashita, Takeshi ;
Murata, Ryoichi ;
Ueda, Mikio ;
Nakao, Shinji ;
Matsue, Kosei .
BLOOD, 2019, 134
[35]   A comparison between next-generation sequencing and ASO-qPCR for minimal residual disease detection in multiple myeloma [J].
Takamatsu, Hiroyuki ;
Murata, Ryoichi ;
Zheng, Jianbiao ;
Moorhead, Martin ;
Terasaki, Yasushi ;
Yoshida, Takashi ;
Faham, Malek ;
Nakao, Shinji .
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
[36]   A COMPARISON BETWEEN NEXT-GENERATION SEQUENCING AND ASO-QPCR FOR MINIMAL RESIDUAL DISEASE DETECTION IN MULTIPLE MYELOMA [J].
Takamatsu, H. ;
Murata, R. ;
Zheng, J. ;
Moorhead, M. ;
Terasaki, Y. ;
Yoshida, T. ;
Faham, M. ;
Nakao, S. .
HAEMATOLOGICA, 2013, 98 :101-102
[37]   Prognostic Value of Immune Profiling Multiple Myeloma Patients during Minimal Residual Disease Monitoring in the Pethema/GEM2010MAS65 Study [J].
Arana, Paula ;
Paiva, Bruno ;
Puig, Noemi ;
Cedena, Teresa ;
Cordon, Lourdes ;
Belen Vidriales, Maria ;
Martinez-Lopez, Joaquin ;
Ocio, Enrique M. ;
Hernandez, Miguel T. ;
Isabel Teruel, Ana ;
Gironella, Mercedes ;
Asuncion Echeveste, M. ;
Rosinol, Laura ;
Martinez, Rafael ;
Oriol, Albert ;
Blade, Joan ;
Jose Lahuerta, Juan ;
Mateos, Maria-Victoria ;
San Miguel, Jesus .
BLOOD, 2015, 126 (23)
[38]   Impact of minimal residual disease (MRD) in salvage autologous stem cell transplantation for relapsed myeloma: results from the NCRI Myeloma X (intensive) trial [J].
Ruth M. de Tute ;
Gordon Cook ;
David A. Cairns ;
Julia M. Brown ;
Jamie Cavenagh ;
A. John Ashcroft ;
John A. Snowden ;
Kwee Yong ;
Eleni Tholouli ;
Matthew Jenner ;
Anna Hockaday ;
Mark T. Drayson ;
Treen C. M. Morris ;
Andy C. Rawstron ;
Roger G. Owen .
Bone Marrow Transplantation, 2024, 59 :431-434
[39]   Impact of minimal residual disease (MRD) in salvage autologous stem cell transplantation for relapsed myeloma: results from the NCRI Myeloma X (intensive) trial [J].
de Tute, Ruth M. ;
Cook, Gordon ;
Cairns, David A. ;
Brown, Julia M. ;
Cavenagh, Jamie ;
Ashcroft, A. John ;
Snowden, John A. ;
Yong, Kwee ;
Tholouli, Eleni ;
Jenner, Matthew ;
Hockaday, Anna ;
Drayson, Mark T. ;
Morris, Treen C. M. ;
Rawstron, Andy C. ;
Owen, Roger G. .
BONE MARROW TRANSPLANTATION, 2024, 59 (03) :431-434
[40]   Minimal Residual Disease in Autografts and Bone Marrow of Patients with Multiple Myeloma: 8-Color Multiparameter Flow Cytometry (EuroFlow- NGF) Vs. Next-Generation Sequencing [J].
Takamatsu, Hiroyuki ;
Takezako, Naoki ;
Yoroidaka, Takeshi ;
Yamashita, Takeshi ;
Murata, Ryoichi ;
Yamazaki, Atsuko ;
Takeuchi, Masahiro ;
Mimura, Naoya ;
Nakaseko, Chiaki ;
Sakaida, Emiko ;
Onoda, Masahiro ;
Utsu, Yoshikazu ;
Fukazawa, Motoharu ;
Matsue, Kosei ;
Nakao, Shinji .
BLOOD, 2020, 136
12345